Can a female patient with a stable benign thyroid nodule be started on a GLP‑1 receptor agonist (e.g., liraglutide)?

GLP-1 Receptor Agonists Can Be Used in Patients with Stable Benign Thyroid Nodules

A patient with a stable benign thyroid nodule can safely start GLP-1 receptor agonist therapy. The primary contraindication for GLP-1 RAs is a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN2)—not benign thyroid nodules 1.

Key Contraindications (What Actually Matters)

The FDA black-box warning and drug labeling for liraglutide explicitly state that GLP-1 RAs should not be used in patients with 1:

• Personal or family history of medullary thyroid carcinoma (MTC)
• Multiple endocrine neoplasia syndrome type 2A or 2B (MEN2)

Benign thyroid nodules are not listed as a contraindication. The rodent studies showing C-cell tumors involved medullary thyroid cancer specifically, and human relevance remains unknown 1.

Evidence on Thyroid Cancer Risk

What the Guidelines Say:

Multiple professional societies confirm GLP-1 RAs are safe in the absence of MTC/MEN2 history:

• The 2022 AACE diabetes guidelines state there is no evidence that incretin-based therapies increase risk for medullary thyroid carcinoma in humans, as human C-cells do not express GLP-1 receptors like rodent C-cells do 2
• The 2015 Italian endocrinology guidelines recommend avoiding GLP-1 analogs only in individuals with personal or family history of medullary thyroid carcinoma or MEN2 3
• The 2022 AGA obesity guidelines conditionally recommend liraglutide and semaglutide without restrictions for benign nodules 4

What Recent Research Shows:

The most comprehensive 2026 analysis of 101,732 participants across 93 clinical trials (206,950 patient-years of exposure) found no association between liraglutide or semaglutide use and thyroid cancer risk in adults 5. While one 2025 study suggested increased thyroid cancer detection in the first year of GLP-1 RA use (HR 1.85), this likely represents enhanced surveillance and early detection bias rather than causation 6. A 2026 study of 1,072 patients with differentiated thyroid cancer found GLP-1 RA exposure was not associated with disease recurrence or progression (HR 0.87, P=0.39) 7.

Clinical Approach for Your Patient

Before Starting GLP-1 RA:

1. Confirm the nodule is truly benign: Review prior FNA cytology showing Bethesda II (benign) or confirm the nodule meets criteria for observation per AACE 2016 guidelines 8
2. Screen for MTC/MEN2 contraindications: Ask specifically about:
   • Personal history of medullary thyroid cancer
   • Family history of medullary thyroid cancer
   • Family history of MEN2 syndrome
3. No routine calcitonin testing needed: Meta-analyses show no relationship between liraglutide therapy and plasma calcitonin elevation 9

During GLP-1 RA Treatment:

• Continue standard surveillance for the benign nodule per AACE guidelines: clinical and ultrasound follow-up, with repeat FNA only if suspicious features develop or substantial progressive enlargement (>50% volume increase) occurs 8
• Do not perform additional thyroid screening beyond what would be done for the nodule itself—recent data show problematic overscreening of patients on GLP-1 RAs leading to unnecessary interventions 10

Important Caveats

Avoid the overscreening trap: A 2026 study documented a concerning trend of endocrinologists ordering thyroid ultrasounds at GLP-1 RA initiation despite no guideline recommendation, leading to a cascade of unnecessary biopsies and surgeries with only 2.4% malignancy rate 10. The malignancy rate in patients prescribed GLP-1 RAs remains low, and strong clinical suspicion—not routine screening—should govern evaluation 10.

The rodent data does not translate to humans: While liraglutide caused dose-dependent C-cell adenomas and carcinomas in mice and rats 1, human C-cells lack the GLP-1 receptor density seen in rodents, and no medullary thyroid cancer has been detected in humans taking liraglutide across extensive clinical trial data 9.

Monitor for symptoms, not labs: Counsel your patient to report neck lumps, hoarseness, dysphagia, or dyspnea 1, but routine calcitonin monitoring is not indicated 9.